Vaccines are available against human papillomavirus (HPV), the causal agent of cervical
and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial …

INTRODUCTION.: There are some 30–40 genotypes of human papillomavirus (HPV) that
cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and …

The currently licensed human papillomavirus (HPV) vaccines are safe and highly effective at
preventing HPV infection for a select number of papillomavirus types, thus decreasing the …

Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …

Cervical cancer is the second leading cause of cancer deaths in women worldwide and HPV
infection is responsible for the development of this cancer. Effective vaccination against HPV …

An association between human papillomavirus (HPV) infection and the development of
cervical cancer was initially suggested over 30 years ago, and today there is clear evidence …

Background Human papillomavirus (HPV) is a sexually transmitted infection (STI) of global
importance; it is the most prevalent STI in the United States, with strains causally linked to …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …

The evidence that high‐risk HPV infections cause cervical cancers has led to two new
approaches for cervical cancer control: vaccination to prevent HPV infections, and HPV …